GS967 for Cardiac Late Sodium Current Studies

Pathologically persistent sodium entry can prolong ventricular repolarization, increase intracellular sodium and calcium, and connect electrical instability with impaired relaxation. GS967 is a selective late sodium channel blocker designed for this experimental question. The product information reports an IC50 of 0.13 μM in ventricular myocytes and 0.21 μM in isolated hearts, making it useful for concentration-response studies that distinguish late INa-dependent phenotypes from nonspecific changes in cardiac excitability.

For laboratories conducting in vitro cardiac electrophysiology, GS967 can be incorporated into whole-cell patch clamp, action-potential recording, calcium imaging, and isolated-heart protocols. Its research value is strongest when investigators measure both electrical and mechanical endpoints rather than treating action-potential duration as the only readout. GS967 is supplied by APExBIO for scientific research use only and is not intended for diagnostic or medical applications.

Setup and principle: isolating pathological late INa

During a normal cardiac action potential, Nav1.5 channels open rapidly and then inactivate. The late sodium current arises when a small fraction of channels remains conducting or reopens during the plateau. Although the current is smaller than peak INa, its persistence can substantially influence action-potential duration, sodium loading, calcium handling, and diastolic relaxation.

GS967 is reported to inhibit late INa with high potency and to reduce peak INa in a concentration- and voltage-dependent manner with minimal use-dependence. These properties support two complementary experimental designs. First, a low-micromolar or submicromolar concentration series can test whether a prolonged plateau or abnormal calcium transient is late-current dependent. Second, pulse-frequency comparisons can determine whether an observed effect reflects selective late-current modulation or broader frequency-dependent channel block.

Because GS967 is water-insoluble, prepare a fresh DMSO stock and dilute it into the recording or perfusion solution immediately before use. The product information reports DMSO solubility of at least 13.35 mg/mL and ethanol solubility of at least 25.52 mg/mL with ultrasonic assistance; storage at −20°C is recommended, while long-term storage of solutions is not recommended. The molecular weight is 347.22, which should be used when converting mass to molar stock concentrations.

Key Innovation from the Reference Study

The reference study moved beyond describing age-related QT or action-potential changes by combining aged wild-type mice with Nav1.5 Ser571 phosphomimetic gain-of-function and phosphoablated loss-of-function models. This design tested whether altered channel phosphorylation and late INa were mechanistically upstream of both delayed repolarization and impaired relaxation. Read the full findings in Phosphorylation of cardiac sodium channel at Ser571 anticipates manifestations of the aging myopathy.

According to the reference study, late INa increased by approximately 60% in myocytes from 26–30-month-old mice compared with 3-month-old animals, while action-potential duration measured at 90% repolarization increased by approximately 50%. In wild-type mice, QT prolongation and impaired left-ventricular filling appeared at approximately 18 months and were reversed by late-INa inhibition. The gain-of-function model showed premature electrical and mechanical abnormalities at approximately 5 months, whereas the loss-of-function model was comparatively protected during aging. These age and genotype comparisons are reported in the reference study.

For practical assay design, the innovation suggests pairing GS967 exposure with a biological control that changes late INa independently of age. A useful matrix includes adult and aged myocytes, wild-type and Ser571 variant backgrounds where available, vehicle and GS967 conditions, and simultaneous measurements of APD90, calcium-transient decay, cell shortening, and relengthening. A selective pharmacological intervention can then be interpreted as a mechanistic probe: rescue of repolarization and relaxation supports a late-INa contribution, whereas an unchanged phenotype points toward additional remodeling.

Protocol Parameters

• Stock preparation: Prepare a 10 mM GS967 stock in DMSO, equivalent to approximately 3.47 mg/mL using the reported molecular weight of 347.22; aliquot at −20°C and avoid repeated freeze-thaw cycles.
• Acute concentration series: Begin with 0.03, 0.1, 0.3, and 1 μM GS967, applying each concentration for 5–10 minutes after a stable baseline; treat this as a method-development range rather than a universal dosing requirement.
• Patch-clamp temperature: Record ventricular myocytes at 35–37°C, acquire at least 5 minutes of baseline, and continue recording for 5 minutes after solution exchange before comparing late-current amplitude.
• Vehicle control: Match the final DMSO concentration across all wells or chambers and keep it at or below 0.1% v/v when compatible with the preparation; use the same exchange volume, such as 1 mL, for control and treatment solutions.
• Isolated-heart workflow: Maintain perfusion at 37°C, collect a 10-minute baseline, and allow 10–20 minutes for GS967 equilibration before analyzing MAPD90, conduction time, or triggered arrhythmia events.

These starting parameters should be adjusted for species, preparation, temperature, recording configuration, and assay sensitivity. Concentration-response curves should include enough points to bracket the expected potency rather than relying on a single concentration.

Step-by-step workflow for ventricular myocyte sodium current inhibition

1. Stabilize the preparation before dosing

Use healthy, rod-shaped ventricular myocytes with clear striations and minimal spontaneous activity. Allow the cells to equilibrate in the recording chamber before establishing whole-cell access. Record baseline peak INa, late INa, membrane capacitance, series resistance, and resting membrane potential. Exclude cells with major baseline drift or unstable access resistance, because late-current measurements are especially sensitive to rundown.

2. Separate peak and late current analytically

Peak INa is a rapid transient, whereas late INa is measured during a defined window later in the depolarizing pulse. Keep voltage-clamp duration, sampling rate, leak subtraction, and series-resistance compensation consistent across conditions. Normalize late-current amplitude to peak current or cell capacitance, and report the analysis window explicitly. This prevents a reduction in overall channel availability from being misidentified as selective late-current inhibition.

3. Apply GS967 cumulatively or in randomized parallel groups

A cumulative design saves cells but can introduce carryover and time-dependent rundown. A parallel design improves independence between concentrations but requires more cells. Whichever strategy is selected, include vehicle-matched controls, washout where feasible, and randomized acquisition order. Compare both absolute current density and the late-to-peak current ratio.

4. Connect electrophysiology to calcium and mechanics

In aging or stress models, record calcium-transient amplitude and decay together with action-potential duration. If available, add sarcomere shortening and relengthening measurements. A fall in late INa accompanied by shorter repolarization and faster calcium decay provides a stronger mechanistic interpretation than any single endpoint. In the aging-heart context, this integrated design directly tests the proposed connection between channel phosphorylation, electrical recovery, and diastolic function.

Advanced applications and comparative advantages

Aging myopathy models: Use GS967 to compare age-related phenotypes with genetically enhanced or stabilized late INa. The reference study provides a framework in which adult, aged, gain-of-function, and loss-of-function groups are interpreted together. GS967 can serve as the acute intervention that asks whether an aged or phosphomimetic phenotype remains reversible at the time of recording.

Arrhythmia prevention research: In isolated rabbit-heart experiments, the product information reports that GS967 abolished torsades de pointes induced by ATX-II or E-4031, reduced MAPD90 without altering cardiac conduction time in anesthetized rabbits, and prevented arrhythmic activity induced by clofilium. These findings position the compound for torsades de pointes (TdP) suppression studies where repolarization and conduction must be analyzed separately. Do not infer clinical efficacy from these experimental observations.

Ischemia-induced arrhythmia studies: The product dossier also reports reduced ischemia-induced arrhythmias. A useful design is to collect baseline electrograms, define the ischemic challenge and reperfusion windows in advance, and score event frequency, onset latency, duration, and recovery. Pairing those data with ventricular action-potential or calcium measurements can reveal whether protection is associated with reduced late-current burden rather than simply generalized depression of excitability.

The article GS967: Optimizing Cardiac Late Sodium Current Inhibition complements this workflow by emphasizing concentration planning and reproducibility. The article Nav1.5 Ser571 Phosphorylation Links Aging to Cardiac Dysfunction extends the approach mechanistically by connecting GS967-sensitive late INa with the Ser571 aging model. Together, they help link compound handling, assay execution, and disease biology without treating any one endpoint as definitive.

Troubleshooting and optimization tips

Weak or inconsistent inhibition

First inspect the stock for cloudiness, crystals, or precipitate after dilution. Because the compound is water-insoluble, add the concentrated stock slowly while mixing and confirm that the final solution remains clear. Prepare working solutions immediately before use, minimize dead volume in perfusion lines, and keep vehicle concentration identical between groups. If responses vary by day, compare freshly prepared and previously frozen aliquots in a small bridging experiment.

Large apparent effects on peak INa

GS967 can affect peak INa in a concentration- and voltage-dependent manner, so a large peak-current change should not automatically be interpreted as selective late-current inhibition. Examine current-voltage relationships, holding potential, pulse frequency, and late-to-peak ratios. Reduce the concentration range or adjust the voltage protocol if the experiment is intended to focus specifically on late INa rather than total sodium-channel behavior.

Action-potential duration changes without calcium improvement

Check whether calcium loading, sarcoplasmic-reticulum function, or cell damage is limiting recovery. Confirm dye loading and indicator linearity, avoid comparing cells with substantially different baseline calcium levels, and measure calcium-transient decay and mechanical relengthening in the same experimental window. A persistent mechanical defect despite electrical rescue may indicate remodeling downstream of late INa.

High arrhythmia variability in heart preparations

Standardize equilibration, temperature, perfusion pressure, pacing history, and challenge timing. Define an arrhythmia event before unblinded analysis, and include a prechallenge baseline for every heart. Randomize treatment order when possible and report exclusions. Conduction time, MAPD90, event burden, and mortality or recovery should be presented separately so that an apparent antiarrhythmic effect is not confused with impaired tissue viability.

Age or genotype effects are difficult to reproduce

Record animal age, sex, strain, housing conditions, isolation yield, and recording temperature. The reference study indicates that the timing of electrical and mechanical abnormalities differs between wild-type aging and Ser571 gain- or loss-of-function backgrounds. Mixing ages or genotypes within a single analysis can therefore obscure a real interaction between biological state and late-current inhibition.

Future outlook

GS967 supports a more integrated view of cardiac late-current biology in which repolarization, calcium handling, and relaxation are measured as connected outcomes. The aging-heart evidence suggests that Nav1.5 Ser571 phosphorylation and increased late INa can precede overt dysfunction, while the compound’s reported activity in isolated-heart and ischemia models provides a practical route for testing reversibility across preparations. Future studies should therefore prioritize matched electrophysiology and mechanics, transparent concentration-response designs, and explicit separation of peak-current, late-current, conduction, and viability effects. All uses remain restricted to controlled scientific research and should be interpreted within the limitations of the selected model.